Atara Biotherapeutics (ATRA) Research & Development (2013 - 2026)

Atara Biotherapeutics has reported Research & Development for 14 years, with the latest figure at $164000.0 in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 99.4% year-over-year to $164000.0; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (down 92.37% YoY), and the FY2025 full-year result was $37.4 million, down 75.28% from the prior year.
• Research & Development for Q1 2026 stood at $164000.0, up from -$223000.0 in the prior quarter.
• The five-year high for Research & Development was $75.0 million in Q1 2022, with the low at -$223000.0 in Q4 2025.
• Historically, Research & Development has averaged $40.4 million across 5 years, with a median of $45.5 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development grew 17.02% — and 2025, when it tumbled 100.78%.
• Atara Biotherapeutics' Research & Development stood at $62.5 million in 2022, then dropped by 20.66% to $49.6 million in 2023, then tumbled by 42.09% to $28.7 million in 2024, then plunged by 100.78% to -$223000.0 in 2025, then surged by 173.54% to $164000.0 in 2026.
• The last three Research & Development figures came in at $164000.0 (Q1 2026), -$223000.0 (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.